Steven A. Feldman, Ph.D.

Steven A. Feldman, Ph.D.
Staff Scientist
Director, Surgery Branch Vector Production Facility
Chair, NIH Institutional Biosafety Committee

Dr. Feldman directs the Surgery Branch Vector Production Facility, which develops and manufactures cGMP quality retroviral and lentiviral vectors encoding T cell receptors or chimeric antigen receptors for the ex vivo genetic modification of T lymphocytes in support of the Branch’s clinical efforts utilizing adoptive cell transfer for the treatment of patients with solid cancers and hematologic malignancies. Dr. Feldman’s research interests also include development of retroviral and lentiviral packaging cell lines and novel strategies for the large-scale closed cell culture processes to support production of clinical reagents. As a result, the lab is focused on identifying novel tumor-associated antigens and developing T cell receptors and chimeric antigen receptors to re-direct T cells to target specific tumors. Recently, research efforts have been focused on individualized cell therapies targeting immunogenic mutations presented on breast cancers.

Areas of Expertise
immunotherapy, gene therapy, adoptive cell therapy, viral vector development, cell line development, cGMP manufacturing

Contact Info

Steven A. Feldman, Ph.D.
Center for Cancer Research
National Cancer Institute
Building 10 - Magnuson ACRF, Room 1B37A
Bethesda, MD 20892-1201
Ph: 301-496-4269
  • cGMP manufacture of retro/lentiviral vectors encoding T cell or chimeric antigen receptors for ex vivo gene-engineering of T lymphocytes.
  • Development of novel strategies for gene engineering T lymphocytes (retroviral, lentiviral, transposon, gene editing) as well as clinical-scale vector and cell production platforms.
  • Identification of T cell or chimeric antigen receptors targeting novel tumor antigens on solid cancers.
  • Identification of immunogenic mutations (neoantigens) on breast tumors for an individualized cell therapy.
  • Novel methods to improve T lymphocyte function and introduce T cell or chimeric antigen receptors using gene editing techniques.

Selected Publications

  1. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL
    The Lancet. 385(9967): 517-528, 2015. [ Journal Article ]
  2. Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Li YF, El-Gamil M, Rosenberg SA
    Clin. Cancer Res.. 21(5): 1019-1027, 2015. [ Journal Article ]
  3. Yang S, Karne NK, Goff SL, Black MA, Xu H, Bischof D, Cornetta K, Rosenberg SA, Morgan RA, Feldman SA
    Hum Gene Ther. Methods. 23(2): 73-83, 2012. [ Journal Article ]
  4. Feldman SA, Goff SL, Xu H, Black MA, Kochenderfer JN, Johnson LA, Yang JC, Wang Q, Parkhurst MR, Cross S, Morgan RA, Cornetta K, Rosenberg SA
    Hum Gene Ther.. 22(1): 107-115, 2011. [ Journal Article ]
  5. Beane JD, Lee G, Zheng Z, Mendel M, Abate-Daga D, Bharathan M, Black M, Gandhi N, Yu Z, Chandran S, Giedlin M, Ando D, Miller J, Paschon D, Guschin D, Rebar EJ, Reik A, Holmes MC, Gregory PD, Restifo NP, Rosenberg SA, Morgan RA, Feldman SA.
    Mol Ther. 23(8): 1380-90, 2015. [ Journal Article ]

Dr. Feldman received his B.A., M.P.H., and Ph.D. from University of California, Berkeley. As a National Reseach Council fellow, he studied mechanisms of viral entry at the FDA's Centers for Biologics Evaluation and Research followed by an addtional NIH fellowhsip investigating the mechanisms of retroviral entry into host cells. Dr. Feldman then spent three years at a leading biotechnology company as the Senior Scientist in charge of process development for the manufacturing of viral vectors and vaccines before coming back to the Surgery Branch of the National Cancer Institute to establish a new Retro/Lentiviral Vector Core Facility.

Name Position
Mary Black Biologist
Harshini Chinnasamy Biologist
Hui Xu Biologist
Nikolaos Zacharakis Ph.D. Research Fellow